How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,868 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

15841. Participation, roles, and the dynamics of change in a group-delivered self-management course for people living with HIV. (PubMed)

Participation, roles, and the dynamics of change in a group-delivered self-management course for people living with HIV. Interventions designed to change behavior delivered to groups rather than individuals are popular in health promotion and self-management. The 7-week positive self-management program (PSMP) for people with HIV status is adapted from a psychoeducational program designed to increase people's capacity to manage their conditions by enhancing self-efficacy. A case study using

2007 Qualitative Health Research

15842. Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. (PubMed)

Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. To describe the clinical response to antituberculosis therapy in HIV-1 disease, 49 HIV-1 positive Ugandan adults (mean age 29.4 years; 68% men) with active pulmonary tuberculosis (PTB) were studied in a trial of rifampicin containing short-course antituberculosisis regimens. At presentation, 18 patients were PPD non-reactors (PPD skin test induration < 2mm), ten (...) /microliters (OR 9.8), cavitary lung disease, (OR 0.6), atypical chest radiograph, (OR 6.7), and PPD non-reactivity, (OR 13.5), PPD non-reactivity and non-cavitary disease were associated with significantly lower CD4 lymphocyte counts. Affordable serial measurements parallel the response to therapy and predict survival in HIV-associated PTB.

1997 East African medical journal

15843. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. (PubMed)

Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. In Africa, the risk of mother-to-child transmission of HIV-1 infection is high. Short-course perinatal oral zidovudine might decrease the rate of transmission. We assessed the safety and efficacy of such a regimen among HIV-1-seropositive breastfeeding women in Abidjan, Côte d'Ivoire.From April, 1996, to February, 1998, all consenting, eligible HIV-1-seropositive (...) . The estimated risk of HIV-1 transmission in the placebo and zidovudine groups were 21.7% and 12.2% (p=0.05) at 4 weeks, and 24.9% and 15.7% (p=0.07) at 3 months. Efficacy was 44% (95% CI -1 to 69) at age 4 weeks and 37% (-5 to 63) at 3 months.Short-course oral zidovudine was safe, well tolerated, and decreased mother-to-child transmission of HIV-1 at age 3 months. Substantial efforts will be needed to ensure successful widespread implementation of such a regimen.

1999 Lancet

15844. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. (PubMed)

Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Large reductions in transmission of HIV-1 from mother to child have been achieved in more-developed countries due to the use of antiretrovirals. Short-course regimens, suitable for resource-poor countries, have also been shown to significantly reduce (...) peripartum HIV-1 transmission. We assessed the efficacy of short-course regimens with zidovudine and lamivudine in a predominantly breastfeeding population.We did a randomised, double-blind, placebo-controlled trial in South Africa, Uganda, and Tanzania. Between June, 1996, and January, 2000, HIV-1-infected mothers were randomised to one of four regimens: A, zidovudine plus lamivudine starting at 36 weeks' gestation, followed by oral intrapartum dosing and by 7 days' postpartum dosing of mothers

2002 Lancet

15845. Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00090779 Recruitment Status : Terminated (The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would

2004 Clinical Trials

15846. Three Month Course of Anti-HIV Medications for People Recently Infected With HIV

Three Month Course of Anti-HIV Medications for People Recently Infected With HIV Three Month Course of Anti-HIV Medications for People Recently Infected With HIV - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Three Month Course of Anti-HIV Medications for People Recently Infected With HIV The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00087464 Recruitment Status : Withdrawn (study was withdrawn before any participants were recruited and enrolled) First Posted : July 13, 2004 Last Update Posted

2004 Clinical Trials

15847. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. (PubMed)

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Many developing countries have not implemented the AIDS Clinical Trials Group 076 zidovudine regimen for prevention of perinatal HIV-1 transmission because of its complexity and cost. We investigated the safety and efficacy of short-course oral zidovudine administered during late pregnancy and labour.In a randomised, double (...) -24.2) on placebo (p=0.006; efficacy 50.1% [15.4-70.6]). Between enrolment and delivery, women in the zidovudine group had a mean decrease in viral load of 0.56 log. About 80% of the treatment effect was explained by lowered maternal viral concentrations at delivery.A short course of twice-daily oral zidovudine was safe and well tolerated and, in the absence of breastfeeding, can lessen the risk for mother-to-child HIV-1 transmission by half. This regimen could prevent many HIV-1 infections during

1999 Lancet

15848. Short course of AZT halves HIV-1 perinatal transmission. (PubMed)

Short course of AZT halves HIV-1 perinatal transmission. 9500334 1998 03 17 2015 06 16 0140-6736 351 9103 1998 Feb 28 Lancet (London, England) Lancet Short course of AZT halves HIV-1 perinatal transmission. 651 Morris K K eng Clinical Trial News Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Anti-HIV Agents 4B9XT59T7S Zidovudine AIM IM J X Anti-HIV Agents administration & dosage Drug Administration Schedule Female HIV Infections prevention & control transmission HIV-1 Humans (...) , led to an 8% mother-to-child HIV transmission rate compared to 23% with placebo. Drug therapy proven in the ACTG 076 trial has now become the basis for current practice in developed countries. Placebo-controlled clinical trials were later launched in selected developing countries to assess the effect upon vertical transmission of providing only a short course of AZT therapy to HIV-infected mothers. In Thailand, 397 HIV-infected pregnant women were randomized to take orally either placebo or 300 mg

1998 Lancet (London, England)

15849. More severe course of delta hepatitis in HIV-infected patients [L] (PubMed)

More severe course of delta hepatitis in HIV-infected patients [L] 7744408 1995 06 12 2018 11 13 0266-4348 71 2 1995 Apr Genitourinary medicine Genitourin Med More severe course of delta hepatitis in HIV-infected patients [L]. 132-3 de Pouplana M M Soriano V V Samaniego J G JG Enríquez A A Muñoz F F González-Lahoz J J eng Letter England Genitourin Med 8503853 0266-4348 EC 2.6.1.2 Alanine Transaminase IM X Adult Alanine Transaminase blood Chronic Disease Female HIV Infections complications

Full Text available with Trip Pro

1995 Genitourinary Medicine

15850. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. (PubMed)

Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. The objective of this case-control study, conducted in a large Italian university hospital over a 12-month period, was to evaluate the risk factors associated with the emergence of azole resistant oral candidosis in 64 Human Immunodeficiency Virus (HIV) infected patients. A swab was obtained from each patient by brushing candidal lesions. Candida albicans was isolated (...) episodes of oral candidosis in the last year (P = 0.01), previous use of azole therapy (P = 0.001), C2-3 category of HIV infection (P = 0.01) and low number of circulating CD4+ T-cells (P = 0.03) were significantly associated with an increased risk for the development of azole resistance. However, previous use of azole therapy was the only factor selected by a stepwise logistic regression analysis which was independently associated with the isolation of azole resistant strains (P = 0.003). Our findings

1996 The Journal of antimicrobial chemotherapy

15851. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. (PubMed)

Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. Human immunodeficiency virus (HIV) levels in cervicovaginal lavage (CVL) and plasma samples were evaluated in relation to perinatal transmission in a randomized placebo-controlled trial of brief antenatal zidovudine treatment. Samples were collected at 38 weeks' gestation from 310 women (...) and more frequently from a subset of 74 women. At 38 weeks, after a 2-week treatment period, CVL HIV-1 was quantifiable in 23% and 52% of samples in the zidovudine and placebo groups, respectively (P<.001). The perinatal transmission rate was 28.7% among women with quantifiable CVL HIV-1 and high plasma virus levels (>10,000 copies/mL) and 1% among women without quantifiable CVL HIV-1 and with low plasma virus levels (P<.001). A 1-log increase in plasma HIV-1 increased the transmission odds 1.8 and 6.1

Full Text available with Trip Pro

2000 The Journal of infectious diseases

15852. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. (PubMed)

Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. Highly active antiretroviral treatment (HAART) was given early to 64 patients with symptomatic primary human immunodeficiency virus (HIV)-1 infection. At the time of analysis, patients had been followed up for 9-21 months. No patient had died or developed an AIDS-defining event. Survival analysis showed that by month 21 the proportion of patients (...) with plasma HIV-1 RNA <50 copies/mL was 72% (95% confidence interval, 58%-95%) in intention-to-treat analysis. After 18 months of treatment, 50% of the patients with undetectable plasma HIV-1 RNA also had undetectable HIV-1 RNA in peripheral blood mononuclear cells (PBMC). Only 1 of 3 patients had undetectable HIV-1 RNA in lymphoid tissue, while all patients had quantifiable HIV-1 DNA both in PBMC and lymphoid tissue. The median CD4 lymphocyte increase from baseline was 230 cells/microL. These preliminary

Full Text available with Trip Pro

1999 The Journal of infectious diseases

15853. Short course zidovudine maternal treatment in HIV-1 vertical transmission: randomized controlled multicenter trial. (PubMed)

Short course zidovudine maternal treatment in HIV-1 vertical transmission: randomized controlled multicenter trial. A multicenter randomized, double blind, placebo-controlled clinical trial was conducted to evaluate the effectiveness of a short course of oral zidovudine (ZDV) treatment in HIV-1 infected pregnant women, starting at 38 weeks of gestation plus ZDV infusion during labor until delivery, to reduce HIV-1 vertical transmission in non-breast fed infants. One hundred and eighty two (...) and normal saline infusion during labor until delivery. HIV-1 transmission was documented by nested polymerase chain reaction in infants at birth and at 1, 3 and, 6 months of age. The estimated HIV-1 vertical transmission rate was 14.9 per cent (95% CI = 11.1 to 18.7) and 16.3 per cent (95% CI = 12.3 to 20.9) in ZDV and placebo group, respectively (p > 0.05). The short course ZDV in antiretroviral naïve pregnant women initiated at 38 weeks' gestation plus intrapartum ZDV infusion without treatment

2001 Journal of the Medical Association of Thailand = Chotmaihet thangphaet

15854. Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. (PubMed)

Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. To describe changes in HIV-1 plasma viral load (VL) and CD4 cell counts and to assess zidovudine resistance associated with a short course of oral zidovudine during late pregnancy.From April 1996 to February 1998 in Abidjan, Côte d'Ivoire, 280 HIV-1-seropositive women were randomly assigned at 36 weeks' gestation to receive zidovudine (300 mg (...) that a short course of zidovudine has no adverse HIV-1 virological consequences for the mother.

2002 AIDS

15855. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. (PubMed)

Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. To assess the 24 month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission (MTCT) of HIV-1 in a breastfeeding population in West Africa.Data were pooled from two clinical trials: DITRAME-ANRS049a conducted in Abidjan, Côte d'Ivoire and Bobo-Dioulasso, Burkina-Faso and RETRO-CI, conducted in Abidjan. Between September (...) , a significant 59% reduction.A maternal short-course zidovudine regimen reduces MTCT of HIV-1 at age 24 months, despite prolonged breastfeeding. However, efficacy was observed only among women with CD4 cell counts > or =500/ml. New interventions should be considered to prevent MTCT, especially for African women with advanced HIV-1 immunodeficiency.

2002 AIDS

15856. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. (PubMed)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. National and international guidelines call for the treatment of primary HIV infection (PHI) with combination antiretroviral therapy, although the ideal timing and duration of this intervention is unknown. Recent immunological studies of antiretroviral therapy on small numbers of patients with PHI have reported preservation of HIV-specific CD4 T-helper responses, ordinarily lost in the absence (...) of intervention. We sought to investigate whether a short course of antiretroviral therapy (SCART) at PHI was sufficient to preserve HIV-specific cellular immunity.Forty-five subjects with confirmed PHI were offered SCART at diagnosis. HIV specific cellular immune responses and virological parameters were assessed at monthly intervals.Thirty-seven of the subjects chose SCART at PHI, and achieved a plasma viral load < 50 RNA copies/ml by a median of 10 weeks (range, 4-32 weeks). Two of the 45 individuals had

2002 AIDS

15857. Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants. (PubMed)

Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants. The perinatal short-course zidovudine (ZDV) chemoprophylaxis that can reduce HIV-1 vertical transmission by 51% has been widely practiced in developing countries such as Thailand because of its simpler and less cost.To investigate the effects of short-course regimen of oral ZDV for prophylaxis of HIV-1 subtype E vertical transmission among 'break-through' HIV-1 (...) infected infants.The study analyzed clinical and virological outcomes of 80 infants, whose mothers received ZDV prophylaxis starting at 36 weeks gestation (group Z) and 37 infants whose mothers never received anti-retroviral drugs (group C), at the ages of 1-2, 4-6, and 12 months.Of the 12 HIV-1 infected infants, 5/7 (71.4%) from group Z and 1/5 (20%) from group C progressed to a symptomatic clinical stage by the age 4-6 months. The intersample nucleotide distance of HIV-1 pol reverse transcriptase (RT

2002 Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

15858. Course and outcome of pregnancy in 54 persistently HIV-1-seronegative sex workers and their infants. (PubMed)

Course and outcome of pregnancy in 54 persistently HIV-1-seronegative sex workers and their infants. To determine the course and outcome of pregnancy in 54 persistently HIV-1-seronegative pregnant commercial sex workers (prostitutes).Five hundred twenty-three initially HIV-1-seronegative prostitutes in Manipur, India, were studied between 1990 and 1999. Two hundred forty (46%) women seroconverted to HIV-1 during the study period. HIV-1 polymerase chain reaction with env, nef and vif gene (...) primers was done on 98 persistently seronegative sex workers, who remained seronegative after three years of follow-up. Fifty-four of these women became pregnant (study group). The course and outcome of pregnancy were studied prospectively in 54 persistently HIV-1-seronegative women and compared with those in matched HIV-1-seronegative women from the general population coming for routine antenatal checkups.In the 54 seronegative women (study group) who became pregnant, there were 52 singleton, term

2002 Journal of Reproductive Medicine

15859. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. (PubMed)

Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. To determine the completion rate and tolerability of short-course rifamycin and pyrazinamide treatment of latent tuberculosis infection (LTBI) in HIV-infected patients through a comprehensive community-based program.Prospective cohort, with comparison to a historical control group.Of 3,118 (...) patients with HIV infection screened for LTBI between February 1999 and March 2001, 135 patients were placed on rifamycin/pyrazinamide for 2 months under directly observed therapy and were compared to a historical group comprised of 93 HIV-infected patients who were placed on self-administered treatment of isoniazid for 12 months between 1996 and 1998.Of 135 patients receiving rifamycin/pyrazinamide, 124 patients (92%) completed treatment; 5 patients had to discontinue treatment due to side effects

2002 Chest

15860. Is the clinical course of HIV infection changing? Study's censoring strategy may be source of bias. (PubMed)

Is the clinical course of HIV infection changing? Study's censoring strategy may be source of bias. 9393248 1997 12 24 2017 11 16 0959-8138 315 7117 1997 Nov 08 BMJ (Clinical research ed.) BMJ Is the clinical course of HIV infection changing? Study's censoring strategy may be source of bias. 1237 Cozzi Lepri A A Phillips A N AN Pezzotti P P Rezza G G eng Letter Comment England BMJ 8900488 0959-8138 AIM IM X BMJ. 1997 Apr 26;314(7089):1232-7 9154026 Bias CD4 Lymphocyte Count Disease Progression (...) HIV Infections mortality HIV Seropositivity Humans 1997 12 11 1997 12 11 0 1 1997 12 11 0 0 ppublish 9393248 PMC2127753

Full Text available with Trip Pro

1997 BMJ : British Medical Journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>